Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Receivables (2025)

Crescent Biopharma (CBIO) has disclosed Receivables for 2 consecutive years, with $18.0 million as the latest value for Q4 2025.

  • For Q4 2025, Receivables changed N/A year-over-year to $18.0 million; the TTM value through Dec 2025 reached $18.0 million, changed N/A, while the annual FY2025 figure was $18.0 million, N/A changed from the prior year.
  • Receivables hit $18.0 million in Q4 2025 for Crescent Biopharma, down from $20.0 million in the prior quarter.
  • Across five years, Receivables topped out at $18.0 million in Q4 2025 and bottomed at $18.0 million in Q4 2025.